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Abstract: 20 
The mechanism of cellular uptake by endocytosis and subsequent oxidative stress has been 21 
identified as the paradigm for the toxic response of cationically surface charged nanoparticles. In 22 
an attempt to circumvent the process, the effect of increased cellular membrane permeability on 23 
the uptake mechanisms of poly (amidoamine) dendrimers generation 4 (G4) and 6 (G6) in vitro 24 
was investigated. Immortalised, non-cancerous human keratinocyte (HaCaT) cells were treated 25 
with DL-Buthionine-(S,R)-sulfoximine (BSO). Active uptake of the particles was monitored 26 
using fluorescence microscopy to identify and quantify endosomal activity and resultant 27 
oxidative stress, manifest as increased levels of reactive oxygen species, monitored using the 28 
carboxy-H2DCFDA dye. Dose dependent cytotoxicity for G4 and G6 exposure was registered 29 
using the cytotoxicity assays Alamar Blue and MTT, from 6 to 72 hours.  30 
Reduced uptake by endocytosis is observed for both dendrimer species. A dramatic change, 31 
compared to untreated cells, is observed in the cytotoxic and oxidative stress response of the 32 
BSO treated cells. The significantly increased mitochondrial activity, dose dependent anti-33 
oxidant behaviour and reduced degree of endocytosis for both dendrimer generations, in BSO 34 
treated cells, indicates enhanced permeability of the cell membrane, resulting in the passive, 35 
diffusive uptake of dendrimers, replacing endocytosis as the primary uptake mechanism. The 36 
complex MTT response reflects the importance of glutathione in maintaining redox balance 37 
within the mitochondria. The study highlights the importance of regulation of this redox balance 38 
for cell metabolism, but also points to the potential of controlling the nanoparticle uptake 39 
mechanisms, and resultant cytotoxicity, with implications for nanomedicine.  40 
41 
 3 
Introduction  42 
Nanoparticle science is a rapidly advancing field which holds much promise in areas such as 43 
targeted drug and gene delivery.
1,2,3
 However, nanoparticle uptake into a cell has been 44 
demonstrated, particularly for nanoparticles with an effective cationic surface charge, to give rise 45 
to cytotoxic responses, raising concerns about the potential health and environmental impact of 46 
the proliferation of nanomaterials in consumer products.
4
 A systematic understanding of the 47 
mechanisms of toxicity and their dependence on nanoparticle physico-chemical properties on a 48 
cellular level is therefore required.
5
 In the context of nanomedical applications, understanding 49 
and controlling the uptake process and subcellular trafficking of the delivery vehicle and the 50 
bioavailability of the cargo are critically important.  51 
 52 
Cellular uptake of nanoparticles principally occurs via endocytosis, whereby the nanoparticle is 53 
invaginated by the cellular membrane and is transported into the cell.
6
 As the low pH 54 
environment of the endosome attempts to digest the nanoparticle, the redox balance of the cell is 55 
disrupted, and, in the case of nanoparticles with an effective cationic surface charge, the process 56 
gives rise to an increase in the production of Reactive Oxygen Species (ROS), localised mainly 57 
around the endosome (or later lysosome).
6,7,8,9
 Although intra cellular anti-oxidants attempt to 58 
neutralise the imbalance, ROS production can be sufficient to lead to oxidative stress.
10
 59 
Subsequently, a cascade of events and the release of several characteristic cytokines and 60 
chemokines occurs, ultimately leading to cell death, a process which is the accepted paradigm of 61 
nanotoxicity of many nanoparticles in vitro.
6
 The process has been well demonstrated for model 62 
nanoparticle system such as amine functionalised polystyrene,
11,12,13
 amorphous nanosilica,
14
 and 63 
nanomeric polymeric dendrimers.
10
 64 
 4 
 65 
Aminated molecules are intrinsic antioxidants, however, and generally regarded as ROS 66 
scavengers. As examples, spermine and spermidine have both been shown to reduce Fe
3+
 to Fe
2+
 67 
15
 and the ferric reducing activity of these molecules has been identified as a measure of anti-68 
oxidant potential.
16
 Carnosine, an endogenous dipeptide, has been shown to scavenge both 69 
reactive oxygen and nitrogen species.
17
 Notably, in a study by Khalid et al. (2015), while the 70 
larger, higher generations of the aminated nanoscale dendrimers Poly (propylene imine) (PPI) 71 
were demonstrated to elicit oxidative stress and significant toxicity, the smaller, lower 72 
generations exhibited intracellular antioxidant behaviour and low toxicity.
18
 Examination of the 73 
uptake mechanisms indicated a transition from cellular uptake by passive diffusion at low 74 
generations to active endocytosis for higher generations. The study suggests that, in the case of 75 
catatonically charge nanoparticles, the endocytotic uptake and trafficking process is, in itself, a 76 
source of cellular toxicity. In the context of drug delivery, invagination of the delivery vehicle 77 
and cargo in this harsh environment may also be undesirable, and although escape by 78 
endosomolysis is a potential strategy,
19
 this too can be a harsh process, causing significant 79 
damage to the cell.
20,21
 For these reasons, circumventing endocytosis appears to be a valid 80 
strategy for the reduction of toxicity associated with aminated nanoparticles as well as 81 
nanoparticle drug or gene delivery. 82 
 83 
Guarnieri et al. (2015), demonstrated that functionalization of aminated polystyrene 84 
nanoparticles with the viral peptide gH625 (derived from Herpes simplex virus – 1), which has a 85 
membrane perturbing domain, enables translocation of particles to the cytoplasm, avoiding 86 
endocytosis and thus, dramatically reducing the cytotoxicity.
22
 An alternative strategy to increase 87 
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the permeability of the cellular membrane, in vitro, is through the application of DL-Buthionine-88 
(S,R)-sulfoximine (BSO). BSO has previously been employed to study the effects of the 89 
reduction of levels of the intracellular antioxidant glutathione (GSH); and therefore oxidative 90 
stress
23,24,25,26
 and has been shown to cause membrane permeabilisation.
27,28
 BSO works as an 91 
inhibitor of the enzyme Glutamate Cysteine Ligase (EC 6.3.2.2) (historically known as gamma-92 
glutamylcysteine synthetase) which is the first step in the production of GSH in the cell.
29
 This 93 
reduction in GSH causes several different effects, one being the induction of the membrane 94 
permeability transition in the mitochondria.
30,31,32
 The opening of this pore and the depletion of 95 
GSH allows ROS to diffuse from the mitochondria to the cell and via lipid peroxidation, cause 96 
damage to the cell membrane,
28
 leading to increased permeability.  97 
 98 
The reduction of GSH in the cell can have other adverse effects, however, mainly due to the fact 99 
that GSH is one of the main antioxidants involved in maintaining the redox balance of the 100 
mitochondria.
33
 In the mitochondria, endogenous ROS is produced as a by-product of normal 101 
metabolism and therefore completely eliminating GSH can leave the cell susceptible to damage 102 
from this ROS.
34
 Furthermore, reductions in cellular GSH can also lead to changes in the 103 
regulation of Ca
2+
 distribution
35,36,37
 and the activation/deactivation of signalling pathways 104 
involved with growth, differentiation and apoptosis.
33,38,39,40
 The loss of GSH and subsequent 105 
changes in the cell have been implicated in several disease states which is reviewed elsewhere.
34
 106 
 107 
This study explores the impact, for HaCaT cell, of BSO treatment on the cellular uptake of, and 108 
subsequent oxidative stress and toxic response to, poly (amido amine) (PAMAM) dendrimers. 109 
These nanoscale aminated dendrimers have a systematically variable molecular structure, and the 110 
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homologous series of increasing generation, and concomitant size and number of surface amino 111 
groups, has been demonstrated to be ideal to study the dependence of nanoparticle cellular 112 
interactions on the physico-chemical properties of the particles. Previous studies have examined 113 
the structurally dependent toxicity, and underlying mechanisms of endocytosis, oxidative stress, 114 
immune responses and consequent toxicity
7,8,9,10
 and the responses have been numerically 115 
modelled, as a guide towards a predictive toxicology approach.
10,41
 For consistency and to allow 116 
comparisons with the previous work, the in vitro studies reported here were also carried out 117 
using the immortalised human keratinocyte cell line, HaCaT, and identical oxidative stress and 118 
cytotoxic assays. Furthermore, PAMAM dendrimers of Generation 4 and 6 were chosen as the 119 
extremes of the previously reported cytotoxicological response. In comparison, it is 120 
demonstrated that treatment with BSO results in a significant change in the nanoparticle uptake 121 
mechanisms and cytotoxicity. 122 
 7 
Materials and Methods 123 
Materials 124 
DMEM F12 HAM growth medium, Penicillin, Streptomycin, fluorescently labelled, Polystyrene 125 
nanoparticles, with amine surface modification (PSNP-NH2) 100nm, DL-Buthionine-(S,R)-126 
sulfoximine(BSO) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) dye 127 
were purchased from Sigma-Aldrich, Ireland. The PAMAM dendrimer nanoparticles, 128 
generations 4 (molecular weight: 14,214 g/mol) and 6 (molecular weight: 58,046 g/mol), were 129 
purchased from Sigma-Aldrich and manufactured by Dendritech Inc. ThiolTracker™ Violet 130 
(TTV), CellLight
®
 Early Endosomes-RFP, BacMam 2.0, Fetal Bovine Serum (FBS), L-131 
Glutamine, Alamar Blue (AB) and 5-(and-6)-carboxy-2',7'-dichlorodihydrofluorescein diacetate 132 
(carboxy-H2DCFDA) dye were purchased from Life Technologies™, Bio-Sciences, Ireland. 133 
HaCaT cells were purchased from Cell Line Services (CLS), Eppelheim, Germany. TrueLine 96-134 
well cell culture plates were used for all viability and ROS studies.  135 
All fluorescence and absorbance readings were taken on a Molecular Devices SpectraMax M3 136 
Spectrometer. Confocal Laser Scanning Fluorescence Microscopy (CLSM) images were taken 137 
on a Zeiss LSM 510 Confocal Laser Scanning Microscope and processed using ImageJ software 138 
(with co-localisation analysis performed with the JaCoP plugin for ImageJ). All viability, ROS 139 
and GSH data analysis was performed using SigmaPlot v10.0 software. 140 
 141 
Methods 142 
Cell culture 143 
HaCaT cells are an immortalised, non cancerous human keratinocyte cell line and were used for 144 
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these experiments. The cells were cultured in DMEM F12 HAM supplemented with 10% FBS, 145 
45 IU/mL penicillin, 45 IU/mL streptomycin and 2mM L-glutamine at 37˚C in 5% CO2. 146 
All assays carried out in this set of experiments were performed in 96 well plates, with cells 147 
plated at a concentration of 1x10
4 cells/well in 100μL of DMEM medium. Cells were allowed 24 148 
hours to attach and were then treated with BSO for an additional 18 hours (at a concentration of 149 
200μM), after which cells were exposed to PAMAM G4 or G6 dendrimers (in DMEM F12 150 
HAM, with 5%FBS, 45 IU/mL penicillin, 45 IU/mL streptomycin, 2mM L-glutamine and 151 
200μM BSO) at various concentrations for the specified time points. Six replicates of each 152 
concentration were performed per plate and each plate was repeated in triplicate.  153 
 154 
ThiolTracker™ Violet (TTV) 155 
ThiolTracker™ Violet (TTV) is a GSH detection agent. Cells were plated as described above and 156 
a concentration gradient of BSO was applied. Cells were left for 18 hours at 37˚C in 5% CO2 to 157 
allow for reduction of the amount of intracellular GSH. Cells were then washed twice with PBS, 158 
100μL of TTV dye (at a final concentration of 20μM) were added to each well and the plates 159 
were allowed to incubate at 37˚C in 5% CO2 for 30 minutes, after which the TTV solution was 160 
removed and replaced with PBS. The fluorescence of each well was then read using the 161 
SpectraMax M3 spectrometer with λEX= 404nm and λEM= 526nm. GSH values were calculated 162 
as compared to the unexposed control. 163 
 164 
Viability assays 165 
Alamar Blue and MTT assays were used to determine the changes in cell viability, after 166 
treatment with BSO as described above, as a result of exposure to both PAMAM G4 and G6 167 
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dendrimers. Both Alamar Blue and MTT were performed on the same plate. The PAMAM G4 168 
concentrations used were: 0.16, 0.32, 0.65, 1.3, 2.6, 5.2, 7.8 and 10.4μM, while the PAMAM G6 169 
concentrations were: 0.08, 0.16, 0.32, 0.65, 1.3, 2.6, 3.9 and 5.2μM. The lower initial value of 170 
the PAMAM G6 dendrimers was used due to their reported EC50 value being much lower than 171 
their G4 counterparts.
7,8,9
 Dose dependent viability percentages were calculated at time points: 6, 172 
12, 24, 48 and 72 hours. Percentage viability was calculated as compared to a control which had 173 
been exposed to 200μM BSO, but had no nanoparticle treatment; this was to ensure any changes 174 
were caused by the nanoparticle and were not the result of BSO treatment. A separate control 175 
where no BSO was present was also performed and showed there was little difference between 176 
cells with no BSO exposure and cells which were exposed to BSO (Supplementary Material, 177 
Figure: S1).  178 
 179 
Alamar Blue (AB) 180 
The Alamar Blue assay was made up from 10X stock solution in medium (DMEM F12 HAM, 181 
with no additional supplements). At the specified time point, the plates were removed from the 182 
incubator and the medium containing PAMAM dendrimer was removed, the cells were washed 183 
with 100μL PBS and then 100μL of DMEM F12 HAM(unsupplemented) containing Alamar 184 
Blue were added to each well. The plates were incubated for 3 hours at 37˚C in 5% CO2 to allow 185 
for conversion of the dye. The fluorescence of each well was then read using the SpectraMax M3 186 
spectrometer with λEX= 555nm and λEM= 585nm. 187 
 188 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 189 
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A stock solution of MTT was made at a concentration of 0.5mg/mL. 500μL of this stock were 190 
added for every 10mL of medium (DMEM F12 HAM, with no additional supplements). At the 191 
specified time point, the plates were removed from the incubator and the medium containing 192 
PAMAM dendrimer was discarded, the cells were washed with 100μL PBS and then 100μL of 193 
DMEM (unsupplemented) containing MTT was added to each well. The plates were incubated 194 
for 3 hours at 37˚C in 5% CO2 to allow for conversion of the dye. After 3 hours, any remaining 195 
dye was removed and each well was again washed with 100μL PBS, after which 100μL of 196 
DMSO was added and the plates were placed on a shaker for 10 minutes to allow for the dye to 197 
solubilise. The absorbance of each well was then read using the SpectraMax M3 spectrometer 198 
with λABS=595nm. 199 
 200 
Reactive Oxygen Species (ROS) 201 
5-(and-6)-carboxy-2',7'-dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA) dye was used 202 
for the detection of ROS. The dye was made up to a final concentration of 10μM in sterile PBS. 203 
Before addition of PAMAM dendrimer, this dye was added to the cells and allowed to incubate 204 
for 1 hour, after which, the dye was removed, the cells were washed thrice with PBS and the 205 
medium containing PAMAM dendrimer was added. At the specified time points the fluorescence 206 
was read by the SpectraMax M3 spectrometer with λEX= 488nm and λEM= 535nm. 207 
 208 
Confocal Laser Scanning Microscopy (CLSM) 209 
Cells were plated onto MatTek 35mm glass bottom dishes at a concentration of 20,000 cells/dish 210 
in DMEM F12 HAM (supplemented with 10% FBS, 45 IU/mL penicillin, 45 IU/mL 211 
streptomycin and 2mM L-glutamine) and allowed to attach for 4 hours, at which point the 212 
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medium was removed and replaced with medium containing Celllight
®
 Early Endosomes-RFP, 213 
BacMam 2.0 at a concentration of 20 particles per cell. Early endosome formation was tracked 214 
with the Celllight
® 
Early Endosome – RFP kit, which transfects, into the cell, a version of Rab5a 215 
with a bound Red Fluorescent Protein. The cells were allowed to incubate (37˚C, 5% CO2) for 16 216 
hours to ensure transfection with the early endosome reagent. After this, the medium was 217 
removed and cells were washed twice with PBS. For cells being tested without BSO, medium 218 
was added for 18 hours (these samples are referred to as untreated cells/untreated controls in the 219 
text), while for cells being tested with BSO, medium containing 200μM BSO was added for 18 220 
hours. Cells were again washed with PBS and carboxy-H2DCFDA was added for 1 hour (10μM 221 
in 2mL PBS), after which cells were again washed twice with PBS. PAMAM dendrimers were 222 
added at a concentration of 3.21μM (G4) and 1μM (G6) and cells were allowed to incubate for 3 223 
hours (G4) or 1 hour (G6) and were then washed twice with PBS and imaged with the Zeiss 224 
LSM 510 Confocal Laser Scanning Microscope. 100nm PSNP-NH2 with attached Green 225 
Florescent Protein was used as a positive control to ensure the Celllight
®
 Early Endosomes-RFP 226 
was functioning as expected; the results of this test are available in the supplementary material 227 
section, Figure S2. Negative controls were also performed with cells which were not exposed to 228 
any nanoparticles, and little to no fluorescence was noted (data not shown). For ROS monitoring, 229 
doses and time points noted above were chosen based on the maximum responses previously 230 
reported in literature.
8
 All confocal images were analysed using ImageJ and co-localisation 231 
studies were performed using Manders split coefficients calculated with the JaCoP plugin for 232 
ImageJ.
42
 233 
 234 
Data Analysis and Statistics 235 
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Data analysis was performed using SigmaPlot™ v10.0 and fluorescence was calculated based on 236 
the values of BSO controls (which were unexposed to nanoparticles, but had been treated with 237 
200μM BSO for 18 hours).  238 
“The cytotoxicity, GSH and ROS experiments were performed in 96-well microplates with six 239 
replicates per plate and each plate repeated three times. Therefore, data points shown represent 240 
the mean of 18 points, with error bars representing ± the standard deviation (as calculated by 241 
SigmaPlot™ v10.0). Confocal Images were taken on a Zeiss LSM 510 and processed using 242 
ImageJ software. Images were taken of eight cells/groups of cells and the images presented in the 243 
manuscript are representative of the sampled cell population.” 244 
 245 
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Results 246 
BSO treatment 247 
While maximising the desired effect of the BSO on the cells, it is important that the viability of 248 
the cells is not affected. TTV showed a 40% reduction in intracellular levels of GSH for the 249 
HaCaT cells upon 200μM BSO exposure for 18 hours (adapted from the methods of: He et al. 250 
(2003)).
24
 This dose and time point were found to have a minimal impact on cellular viability as 251 
measured by the AB and MTT assays (data available in Supplementary Material, Figure: S3). 252 
Higher concentrations were found to have an effect on cellular viability, although a more 253 
pronounced effect was observed by CLSM, where signs of cellular stress were noted (data not 254 
shown). Therefore 200μM BSO exposure was chosen as optimal. 255 
 256 
PAMAM G4 dendrimers 257 
CLSM was employed as a way to examine the effect of BSO treatment on the cellular uptake 258 
mechanisms and subsequent oxidative stress. Early endosome formation was tracked with the 259 
Celllight
® 
Early Endosome – RFP kit and the formation of ROS was also tracked using the 260 
carboxy-H2DCFDA dye. Fluorescently labelled PSNP-NH2 of 100nm diameter were employed 261 
as positive controls, and the results for those are shown in the Supplementary Material: Figure 262 
S2. 263 
 264 
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 265 
Figure 1: CLSM images of HaCaT (live) cells, upon exposure to 3.21μM PAMAM G4 266 
dendrimer at 3 hours (no BSO is present in this sample). Image a) shows the bright field image 267 
of the cells, Image b) shows the fluorescence generated by the early endosomal red fluorescent 268 
protein, Image c) shows the fluorescence generated by the ROS (interacting with the carboxy-269 
H2DCFDA dye) and Image d) shows the overlay of images a-c, where yellow coloured areas 270 
indicate simultaneous endosomal and ROS activity. 271 
 272 
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Figure 1 shows the HaCaT cells following the reported paradigm of PAMAM G4 endocytosis 273 
and subsequent ROS generation at the endosomal sites.
6,7,8,9
 Co-localisation (performed on the 274 
images in Figure 1) shows that 91(±3)% of the generated ROS occurs in the neighbourhood of 275 
endosomes, and that 71(±4)% of endosomal formation resulted in increases in ROS production 276 
(the other 30% of endosomal activity is most likely due to endocytosis which would be routinely 277 
done by the cell and would not involve the dendrimers and therefore not produce ROS).  278 
 279 
 280 
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Figure 2: Confocal images of HaCaT (live) cells, upon exposure to 3.21μM PAMAM G4 281 
dendrimer at 3 hours, with pre-treatment of BSO: 200μM for 18hours. Image a) shows the bright 282 
field image of the cells, Image b) shows the fluorescence generated by the early endosomal red 283 
fluorescent protein, Image c) shows the fluorescence generated by the ROS (interacting with the 284 
carboxy-H2DCFDA dye) and Image d) shows the overlay of images a-c, where yellow coloured 285 
areas indicate simultaneous endosomal and ROS activity.  286 
 287 
In contrast, Figure 2 shows HaCaT cells which have been treated with BSO for 18 hours prior to 288 
PAMAM G4 exposure (BSO was still present in the media upon exposure, to ensure conditions 289 
were consistent). In images (b) and (c), the intensity of the endosomal RFP and ROS dye have 290 
been significantly reduced. Again co-localisation analysis was performed (on images in Figure 2) 291 
and showed that 30(±6)% of the generated ROS was happening around the endosomes, and that 292 
46(±14)% of endosomal formation resulted in increases in ROS production. Intensity analysis of 293 
the red fluorescent protein produced by endocytosis, on average, showed a reduction in intensity 294 
of 70(±3)% for cells treated with BSO.  295 
 296 
Endosomal uptake was clearly reduced, although a decrease in the intensity of response of the 297 
ROS detection dye, carboxy-H2DCFDA, was also noted, prompting a quantitative analysis of the 298 
ROS contents of the HaCaT cells: Figure 3. 299 
 300 
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 301 
Figure 3: Dose dependant generation of ROS in HaCaT cells (shown for 24 hours for the 302 
PAMAM G4). ROS is compared to BSO control which was set to equal 0%. The X-axis is 303 
plotted logarithmically to allow for better visualisation of lower concentrations. Data points are 304 
the mean of 18 samples, with error bars showing (±) the standard deviation. 305 
 306 
The analysis of ROS showed a net decrease at all doses tested; for clarity, only the dose 307 
dependence of the 24 hour test has been shown, the full data-set is available in the supplementary 308 
material section (Figure S4). Over the dose range tested, the ROS response followed a 309 
monotonically decreasing trend. This result, is again, in contrast with previous observations, in 310 
which ROS levels were seen to increase above control levels in a dose dependant fashion, upon 311 
G4 dendrimer exposure.
8
 312 
 313 
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To examine how these changes in both endocytosis and ROS production affected the viability of 314 
the cell AB and MTT assays were performed. HaCaT cells were exposed to 200μM BSO for 18 315 
hours and subsequently exposed to varying concentrations of PAMAM G4 nanoparticles. 316 
Viability was measured at 6, 12, 24, 48 and 72 hours (Figure 4 (a) and (b)).  317 
 318 
(a)             (b) 319 
 320 
Figure 4: Alamar Blue (a) and MTT (b) dose dependant viability results for PAMAM G4 321 
dendrimers in HaCaT cells after 6, 12, 24, 48 and 72 hours. Viability is calculated as the 322 
percentage of living cells as compared to BSO control. Data points are the mean of 18 samples, 323 
with error bars showing (±) the standard deviation. 324 
 325 
The AB assay shows little or no toxicity of PAMAM G4 at time points 6, 12, and 24 hours, 326 
whereas the viability is reduced to 50% at 48 hours and 30% at 72 hours, for the higher dose 327 
exposures. In HaCaT cells which have not been treated with BSO, the EC50 obtained from AB is 328 
around 10μM at 24 hours,7 whereas, in Figure 4, at the same time point, it is clear that there is no 329 
significant toxicity. The MTT results show a dramatically different dose dependent cytotoxicity 330 
profile for the BSO dosed cells compared to un-dosed.
7
 At 6 hours exposure (Figure 4b), the 331 
 19 
viability is seen to be reduced to around 80% over the entire dose range. However, at exposure 332 
times of 12, 24, 48 and 72 hours, increases in viability are seen for the low-medium dose range. 333 
The effect is particularly pronounced at the 48 hour time point, at which the recorded MTT 334 
response is ~175% of control, for an exposure dose of ~1μM. For doses of ~2.6μM and higher, 335 
the MTT assay response registers a decrease in viability, which is more pronounced in the longer 336 
time point exposures. 337 
 338 
PAMAM G6 dendrimers 339 
Analysis of uptake and ROS production was again carried out using CLSM (with the same 340 
method as the PAMAM G4) incorporating the carboxy-H2DCFDA dye and Celllight
® 
Early 341 
Endosome – RFP kit (Figure 5 and 6). 342 
 343 
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 344 
Figure 5: Confocal images of HaCaT (live) cells, upon exposure to 1μM PAMAM G6 dendrimer 345 
at 1 hour (no BSO is present in this sample). Image a) shows the bright field image of the cells, 346 
Image b) shows the fluorescence generated by the early endosomal red fluorescent protein, 347 
Image c) shows the fluorescence generated by the ROS (interacting with the carboxy-H2DCFDA 348 
dye) and Image d) shows the overlay of images a-c, where yellow coloured areas indicate 349 
simultaneous endosomal and ROS activity.  350 
 351 
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In the absence of BSO, PAMAM G6 exposure, resulted in strong red fluorescence indicating a 352 
high level of endocytosis, complemented by strong green fluorescence indicating increased ROS 353 
production. Co-localisation analysis (of images in Figure 5) found that 75(±2)% of the generated 354 
ROS occurred in the region of the endosomes, and that 92(±1)% of endocytosis resulted in 355 
increases in ROS production. This strong level of co-localisation is indicative of the accepted 356 
paradigm of nanoparticle uptake by endocytosis, and ROS production at the site of endosomes. 357 
 358 
 359 
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Figure 6: Confocal images of HaCaT (live) cells, upon exposure to 1μM PAMAM G6 dendrimer 360 
at 1 hour, with pre-treatment of BSO: 200μM. Image a) shows the bright field image of the cells, 361 
Image b) shows the fluorescence generated by the early endosomal red fluorescent protein, 362 
Image c) shows the fluorescence generated by the ROS (interacting with the carboxy-H2DCFDA 363 
dye) and Image d) shows the overlay of images a-c, where yellow coloured areas indicate 364 
simultaneous endosomal and ROS activity.  365 
 366 
In comparison to exposure of PAMAM G6 in cells without BSO treatment (untreated cells), 367 
there is a sparsity of endosomal activity and oxidative stress response in cells which had been 368 
pre-treated with BSO for 18 hours. Analysis (of the images in Figure 6) showed decreased levels 369 
of co-localisation between the ROS and endosomal formation: only 41(±18)% of ROS 370 
production was recorded in areas where endosomes had formed and 55(±10)% of endocytosis 371 
resulted in increases in ROS production. Intensity analysis of the red fluorescent protein 372 
produced by endocytosis, on average, showed a reduction in intensity of 61(±1)% for cells 373 
treated with BSO when compared to the untreated cells. 374 
 375 
Again, in light of the reduced ROS response, quantitative analysis, using carboxy-H2DCFDA 376 
was performed: Figure 7. 377 
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 378 
Figure 7: Dose dependant generation of ROS in HaCaT cells (shown at 24 hours for the 379 
PAMAM G6). ROS is compared to BSO control which was set to equal 0%. The X-axis is 380 
plotted logarithmically to allow for better visualisation of lower concentrations. Data points are 381 
the mean of 18 samples, with error bars showing (±) the standard deviation. 382 
 383 
The dose response of the ROS generation shows similarities with the G4 in the overall 384 
progression of the response, pointing to a trend where increasing concentration leads to 385 
decreasing amounts of ROS, contrary to what has been observed in previous studies without 386 
BSO exposure.
8
 As with the G4 analysis, for clarity, only one of the eight concentrations tested 387 
have been shown, the full data-set is available in the supplementary material section (Figure S5). 388 
At all doses tested, the ROS response followed the same trend as shown in Figure 7. 389 
 390 
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To analyse the effect this had on viability, AB and MTT assays were performed: Figure 8. 391 
 392 
(a)             (b) 393 
394 
Figure 8: Alamar Blue (a) and MTT (b) dose dependant toxicity results for PAMAM G6 395 
dendrimers in HaCaT cells after 6, 12, 24, 48 and 72 hours. Viability is calculated as the 396 
percentage of living cells as compared to a BSO control. The X-axis is plotted logarithmically to 397 
allow for better visualisation of lower doses. Data points are the mean of 18 samples, with error 398 
bars showing (±) the standard deviation. 399 
 400 
The viability results of the PAMAM G6 dendrimers are similar to those observed in the G4 401 
analysis. In Figure 8, for 6 and 12 hour exposure, little toxicity is recorded by AB, although the 402 
response is significantly stronger at the later time points. The previously reported EC50 obtained 403 
form the AB assay for PAMAM G6 dendrimers is in the range of 1μM-1.6μM at 24 hours,8 404 
which would appear to agree with the values obtained in this study. However, as was the case for 405 
PAMAM G4 exposure, the MTT assay registers increased percentage viability, compared to 406 
BSO control, for the intermediate doses, for all but the 6 hour exposure time point. A cytotoxic 407 
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response is elicited for doses greater than 1μM, for the 24, 48 and 72 hour time points and the 408 
response is consistent with the previously reported EC50 values of 0.92μM-1.13μM.
7
 409 
 410 
PAMAM G4-G6 Comparative Analysis 411 
PAMAM nanoparticle toxicity is a generation dependant process,
7,8,9
 therefore, a comparison of 412 
the response of BSO treated cells to G4 and G6 dendrimer exposure was performed, to establish 413 
whether a similar generation dependence of the cellular responses is still evident. 414 
 415 
The AB and MTT assays were compared for PAMAM G4 and G6 dendrimers, and the results 416 
are shown in Figures 9 (AB) and 10 (MTT). For both dendrimers, approximately equivalent 417 
concentration ranges were used, although, for the PAMAM G6 dendrimers, a slightly lower 418 
initial concentration was used due to the higher associated toxicity.
7,8,9,10
 419 
 420 
a)              b) 421 
 422 
Figure 9: Alamar Blue (AB) dose dependant toxicity results comparing the PAMAM G4 and G6 423 
dendrimers in HaCaT cells after 48 hours (a) and 72 hours (b). Viability is calculated as the 424 
percentage of living cells as compared to BSO control. The x-axis is plotted logarithmically to 425 
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allow for better visualisation of lower doses. Data points are the mean of 18 samples, with error 426 
bars showing (±) the standard deviation. 6, 12 and 24 hour graphs can be seen in the 427 
supplementary material section (Figure S6). 428 
 429 
Little or no significant cytotoxicity was registered by the AB assay for either dendrimer at the 6 430 
and 12 hour time points. At 24 hours, the higher toxicity associated with the G6 dendrimers 431 
becomes apparent, while the G4 still shows no significant change (Supplementary Material: 432 
Figure S6, c). At 48 hours (Figure 9(a)) the G4 dendrimers begin to elicit a significant toxic 433 
response and finally, at 72 hours (Figure 9(b)), the G4 toxic profile is beginning to match that of 434 
G6, although the reduction of viability is much higher for G6. 435 
 436 
a)              b) 437 
438 
Figure 10: MTT dose dependant toxicity results comparing the PAMAM G4 and G6 dendrimers 439 
in HaCaT cells after 48 hours (a) and 72 hours (b). Viability is calculated as the percentage of 440 
living cells as compared to BSO control. The X-axis is plotted logarithmically to allow for better 441 
visualisation of lower doses. Data points are the mean of 18 samples, with error bars showing (±) 442 
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the standard deviation. 6, 12 and 24 hour graphs can be seen in the supplementary material 443 
section (Figure S7). 444 
 445 
In the MTT, similar to AB response, no significant difference was seen in the 6 hour analysis for 446 
the two dendrimers, although differences become apparent at 12 hours (Supplementary Material: 447 
Figure S7, b), at which point the MTT response increases above that of controls for the G6 448 
dendrimer. This increase in MTT response also occurs for the G4 dendrimers, although, it is not 449 
manifest until the later time point of 48 hours (Figure 10(a)). Similar to the AB response, 450 
cytotoxicity is registered by the MTT assay for both dendrimers beginning at 24 hours; however, 451 
the AB only reaches about 50% viability. At 48 and 72 hours a more complete toxic profile for 452 
both assays is seen and distinct generation dependence is observable, more consistent with that 453 
observed for untreated cells.
7
 454 
 455 
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 456 
Figure 11: Dose dependant generation of ROS in HaCaT cells (shown at 24 hours for PAMAM 457 
G4 and G6). Data is compared to BSO control which was set to equal 0%. The X-axis is plotted 458 
logarithmically to allow for better visualisation of lower concentrations. Data points are the mean 459 
of 18 samples, with error bars showing (±) the standard deviation. 460 
 461 
To further investigate any generation dependence, the dose response of the ROS was compared 462 
for the G4 and the G6 (Figure 11). It is notable that the generation dependence of the trends is 463 
reversed in Figure11 where G4 elicits a more pronounced reduction in ROS levels than G6. 464 
465 
 29 
Discussion 466 
The confocal images of Figures: 1 and 2 (PAMAM G4) and Figures: 5 and 6 (PAMAM G6) 467 
show that, for cells treated with 200μM BSO for 18 hours prior to PAMAM exposure, the rate of 468 
endocytosis has been markedly reduced. This reduction in endocytosis is accompanied by a 469 
similar reduction in intracellular ROS and a dramatic change in the responses of the cytotoxic 470 
assays. Nevertheless, the observed reduction of intracellular ROS and cytotoxic responses are 471 
systematically dependent on dendrimer exposure time, dose and generation, consistent with the 472 
intracellular action of the dendritic nanoparticles. 473 
 474 
The demonstrated mechanism of PAMAM dendrimer toxicity is one of endocytosis,
8,43,44
 ROS 475 
production,
7,8,9,18
 subsequent endosomolysis, whereby the nanoparticle bursts out of the 476 
endosome/lysosome into the cytosol,
19
 and localisation in the mitochondria.
45
 Mukherjee and 477 
Byrne (2013) identified two apoptotic pathways, the death-receptor pathway (extrinsic, Fas 478 
mediated FADD pathway
46
) and the mitochondrial pathway (intrinsic, TNF-α mediated 479 
FADD
47
).
10
 The former is initiated by the earlier stage ROS generation in the region of the 480 
endosomes, while the latter is initiated by the localisation of the dendrimers in the mitochondria. 481 
It has been proposed that the early stage ROS production is due to the action of NADPH 482 
oxidase
6
 (producing superoxide anions (O2
-
)
48
) and the v-ATPase proton pump (providing 483 
protons,
49
 ultimately leading to production of H2O2
50
 in and around the endosome. In cells 484 
treated with BSO, however, PAMAM dendrimers elicit a dramatically different cytotoxicity 485 
profile, as registered by the AB and MTT assays, compared to that of untreated cells.
7,8
 486 
 487 
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Studies by Khalid et al. (2015) of cellular uptake of PPI dendrimers have demonstrated that, 488 
although the larger generation PPI dendrimers are endocytosed and elicit similar responses to 489 
PAMAM equivalents in HaCaT cells, for smaller generation PPI dendrimers, uptake by passive 490 
diffusion occurs and, when the dendrimers enter the cell in this way, they were observed to act as 491 
antioxidants and elicit a significantly reduced cytotoxic effect.
18
 BSO exposure has been shown 492 
to permeabilise the cell membrane,
28
 and as a result, it is proposed that the PAMAM G4 and G6 493 
dendrimers are able to circumvent the endocytotic process, are uptaken by passive diffusion, and, 494 
as PAMAM dendrimers are similar in structure to PPI dendrimers and have comparable surface 495 
chemistry, similarly behave as antioxidants in the cytosol, eliciting substantially reduced 496 
cytotoxic responses.  497 
 498 
Alamar Blue is a non-specific assay and measures cellular viability based on the overall activity 499 
of the cytosolic environment.
51
 The significant reduction, rather than expected increase, of 500 
toxicity as registered by this assay reflects the reduction in the endocytosis process (which 501 
initiates the Fas mediated FADD (death-receptor) apoptotic pathway), in favour of the passive 502 
diffusion of nanoparticles across the membrane, and consequent reduction in ROS generation in 503 
the region of endosomes. However, endocytosis is not fully eliminated for either generation, and 504 
therefore, the activation of the Fas mediated pathway, on a much reduced scale, would in part 505 
explain why the generation dependent response is still observed for the PAMAMs. 506 
 507 
The MTT assay measures mitochondrial activity as an indicator of cellular viability
52,53,54
 and, in 508 
the case of the studies described here, the mitochondria are implicated in at least two different 509 
processes and changes in MTT responses reflect the dose and generation dependence of these 510 
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processes at several time points. The first process is the loss of GSH from the cell, which has 511 
been shown to cause activation of mitochondrial signalling pathways and expression of genes 512 
associated with apoptosis, growth and differentiation.
33,38,39,40
 This overall increase in 513 
mitochondrial activity (observed in the low dose regime), is seen as the initial increase in MTT 514 
values above controls, associated with dose and generation dependent decrease in ROS below 515 
controls, due to the antioxidant effect of the passively uptaken dendrimer nanoparticles.  516 
 517 
The second effect gives rise to a sharp decrease in mitochondrial activity (observed in the higher 518 
dose regime); consistent with PAMAM dendrimer localisation and disruption of the 519 
mitochondria,
7,8
 initiating the mitochondrial apoptotic pathway, leading to cell death in a dose 520 
dependant fashion, as observed for untreated cells.
7,8
 This process may be accelerated via the 521 
opening of the mitochondrial membrane permeability transition pore.
30,31,32
 Whether passively 522 
diffused into the cell, or released into the cytosol by endosomolysis after endocytosis, the result 523 
of free PAMAM dendrimers in the cytosol and subsequent localisation to the mitochondria 524 
should be equivalent, both resulting in disruption of the mitochondria, a second phase increase in 525 
ROS within the cell, subsequent decay in the mitochondrial membrane potential and finally the 526 
initiation of a cascade leading to apoptosis.
7,8,9,10
 It should also be noted that in both cases the 527 
opening of the mitochondrial membrane transition pore occurs, either by the action of 528 
BSO,
30,31,32
 or due to the release of the endosomal/lysosomal contents causing intracellular 529 
release of Ca
2+
, leading to calcium dependant opening of the pore.
21
 This would, in both cases, 530 
facilitate the entry of the dendrimer to the mitochondria. As a result, in the high dose regime, the 531 
observed toxic response of the BSO treated cells, as registered by the MTT assay, is not very 532 
different to that observed for untreated cells. 533 
 32 
 534 
The passive diffusion of dendrimers across the cell membrane is a size dependant process
18
 and, 535 
the generation dependence of the cellular responses to the two PAMAM dendrimer generations, 536 
G4 and G6, (Figures: 1, 2, 5 and 6), is consistent with a higher uptake rate for the G4 dendrimer 537 
than the G6. The greater reduction of intensity of Rab-5a-RFP compared to controls (with no 538 
BSO treatment), G4 dendrimers (70%) compared to G6 (60%), indicates a higher diffusion rate 539 
for G4 dendrimers, leaving fewer available for endocytosis. This further explains the higher rate 540 
of anti-oxidative activity exhibited by the G4 dendrimers when compared to G6 (Figure 11). 541 
Overall, it would appear that the membrane has become more permeable to an extent that favours 542 
passive uptake, although not completely eliminating active endocytosis. 543 
 544 
Within the framework of Adverse Outcome Pathways (AOPs), recently endorsed by the 545 
OECD
55,56
 as a method to simplify the representation of the mode of action of a toxicant or 546 
agonist, the generation of ROS can be considered the key Molecular Initiating Event (MIE) of 547 
the AOP, which ultimately leads to the AO of loss of cell viability. The treatment with BSO 548 
causes a depletion of GSH, which would lead to the expectation of much increased ROS levels 549 
after endocytosis. However, that was not observed and the result of the reduction of intrinsic 550 
GSH levels by BSO treatment was predominantly the increased permeability of the cell 551 
membrane, resulting in an increased rate of uptake of the PAMAM dendrimers by passive 552 
diffusion, making it a favoured uptake mechanism, more so for the smaller G4 dendrimer than 553 
the larger G6. The co-existence of the parallel uptake mechanisms increases the complexity of 554 
any model to describe the in vitro system, although it could prove a useful model to develop 555 
networks of AOPs, initiated by different MIEs. However, to fully examine the effect of reduction 556 
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of GSH in terms of decreased anti-oxidant activity alone, an assay which did not cause decrease 557 
of the permeabilisation of the cell membrane would be necessary.  558 
 559 
Considering the potential for PAMAM dendrimers in nanomedical applications, it is important to 560 
note that, when diffused into the cell, the aminated surface chemistry of the dendrimers lend 561 
them antioxidant activity, similar to small molecular anti-oxidants, such as N-acetylcysteine 562 
(NAC) and NAC amide (NACA - a more bio-available version of NAC). NACA has been 563 
extensively studied as an antioxidant in the cell, due to its ability to diffuse across the membrane 564 
and the presence of a terminal proton donor group.
57,58
 Interestingly, it has also been shown to 565 
completely reverse the damage caused to the cell by depletion of GSH.
59,60,61
 NACA, due to this 566 
strong anti-oxidant ability, has been proposed in the treatment of several disorders and diseases, 567 
such as: HIV,
62
 Alzheimer’s and Parkinson’s disease,60,63 cataract formation,59 retinal 568 
degeneration
64
 and essentially any disease where ROS is identified as the potential MIE.
(See: 61 and 
569 
references therein)
 If PAMAM dendrimers are seen to act in a similar way, it may potentially allow for 570 
their use in a plethora of different nano-medical applications. As a strategy for drug release, 571 
endosomolysis can be extremely disruptive to the cell
20
 and therefore, in the case of cationic 572 
nanoparticles for intracellular nanomedical applications, avoiding the process of endocytosis 573 
may be a valid strategy to pursue.
22
 In terms of therapeutic applications, direct entry into the 574 
cytosol may be a more convenient route for drug or gene delivery. 575 
576 
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Conclusions 577 
Although PAMAM dendritic nanoparticles are known to elicit significant cytotoxic responses in 578 
vitro, the cellular response mechanisms can be notably altered by treatment of the cells with 579 
BSO. The treatment increases the cell membrane permeability, enabling uptake of the particles 580 
by passive diffusion, where after, they act as antioxidants in the cytosol, rather than producing 581 
oxidative stress in the region of endosomes. The ability to tune the cellular uptake mechanism 582 
allows direct entry into the cytosol and may have important implications for nanotoxicity as well 583 
as drug and gene delivery using nanovehicles. 584 
585 
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